Drug Trial Radar · NCT07314333
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Feb 5, 2026
Primary completion
Mar 30, 2026
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jan 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
Conditions
- ADHD
Interventions
CentanafadineDrug
Oral, QD XR capsules.
MethylphenidateDrug
Oral tablets.
LisdexamfetamineDrug
Oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Blood Pressure (BP) at Day 12 or Early Termination (ET)Time frame: Baseline, Day 12 or ET
- Change from Baseline in Heart Rate (HR) at Day 12 or ETTime frame: Baseline, Day 12 or ET
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.